A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)
Randomized trial evaluates dapagliflozin's effects on heart failure outcomes in patients, indicating potential benefits.
Key Points
This trial aims to evaluate the effect of dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction.
International, multicenter, randomized double-blind trial with 4744 patients.
Patients with left ventricular ejection fraction ≤ 40% were administered dapagliflozin or placebo.
Primary outcome is a composite of worsening heart failure events or cardiovascular death.
The trial will determine the efficacy and safety of dapagliflozin compared to placebo.
Primary outcomes target 844 events to provide robust conclusions.
Secondary outcomes include total heart failure hospitalizations and cardiovascular death.